

Patient Acceptability and Preferences for Solid Oral Dosage Form Drug Product Attributes: A Scoping Review

Brett Hauber¹, Mark V Hand², Bruno C Hancock³, Joseph Zarrella³, Ljiljana Harding⁴,
Michaela Ogden-Barker⁵, Amy S Antipas³, Stephen J Watt¹

¹Pfizer Inc, New York, NY, USA; ²Pfizer Ireland Pharmaceuticals, Ballinacorney,
Ringaskiddy, Cork, Ireland; ³Pfizer Inc, Groton, CT, USA;
⁴Pfizer ApS, Ballerup, Denmark; ⁵Pfizer Ltd, Sandwich, England, UK

Supplementary Material

Supplementary Table 1. Search Strategy

Search #	Search terms	Records identified
1	'acceptability'/exp OR acceptability OR 'palatability'/exp OR palatability OR swallow* OR 'appearance'/exp OR appearance OR 'taste'/exp OR taste OR 'odor'/exp OR odor OR 'color'/exp OR color OR 'mouth feel' OR mouthfeel OR 'shape'/exp OR shape OR 'coating'/exp OR coating"	1,214,316
2	tablet*:ti' OR 'solid oral' OR 'oral solid' OR 'solid dosage' OR 'tablet formulation' OR 'tablet'/exp OR 'drug capsule' OR 'oral formulation*' OR pill:ti OR pills:ti	86,573
3	#1 AND #2	9965
4	preference* OR acceptab* OR acceptance	668,561
5	#3 AND #4	1493
6	#5 AND (2013:py OR 2014:py OR 2015:py OR 2016:py OR 2017:py OR 2018:py OR 2019:py OR 2020:py OR 2021:py OR 2022:py OR 2023:py)	944
7	preferenc*:ti OR acceptability:ti OR adherence:ti OR palatability:ti OR swallowability:ti OR oral:ti OR solid:ti OR excipient*:ti	508,476
8	#6 AND #7	311
9	#8 NOT ('animal experiment'/de OR 'animal model'/de OR 'animal tissue'/de OR dogs OR cats)	301

Notes: Embase search conducted on May 12, 2023.

Supplementary Table 2. Search Term Keywords

Drug Product	Preference AND	Oral solid AND
<ul style="list-style-type: none">• Acceptability• Appearance• Coating¹• Color/colour²• Feel• Mouth feel• Odor/odour• Palatability• Shape¹• Swallowability• Taste	<ul style="list-style-type: none">• Drug AND shape• Drug AND size• Drug AND tablet• Drug AND capsule• AND excipient	<ul style="list-style-type: none">• Acceptance• Adherence• Excipient³• Formulation

Supplementary Table 3. Disease Classification Among Included Studies

First author (year study published)	Healthy	Life-threatening		Non-life-threatening	
		Symptomatic	Asymptomatic	Symptomatic	Asymptomatic
n (%)	13 (68)	9 (47)	0	10 (53)	2 (11)
Almukainzi (2021) ⁴	✓				
Barenie (2020) ⁵		✓		✓	✓
Bracken (2020) ⁶	✓	✓		✓	
Bracken (2022) ⁷	✓	✓		✓	
Fastø (2019) ⁸		✓		✓	
Goyanes (2017) ⁹	✓				
Hofmanová (2019) ¹⁰	✓				
Hofmanová (2020) ¹¹	✓				
Hummler (2023) ¹²	✓				
Kabeya (2021) ¹³	✓	✓		✓	✓
Kurczewska- Michalak (2020) ¹⁴	✓				
Liu (2016) ¹⁵		✓		✓	
MacKenzie- Smith (2018) ¹⁶				✓	
Osborn (2019) ¹⁷		✓			
Ranmal (2013) ¹⁸	✓	✓		✓	
Shariff (2020) ¹⁹	✓				
Vallet (2020) ²⁰	✓			✓	
Venables (2015) ²¹		✓		✓	
Wargenau (2022) ²²	✓				

References

1. US Food and Drug Administration. Size, shape, and other physical attributes of generic tablets and capsules. US Department of Health and Human Services; 2015. Available from: <https://www.fda.gov/media/87344/download>.
2. Overgaard A, Møller-Sonnergaard J, Christrup LL, Højsted J, Hansen R. Patients' evaluation of shape, size and colour of solid dosage forms. *Pharm World Sci*. 2001;23:185-188.
3. Veronica N, Heng PWS, Liew CV. Ensuring product stability—choosing the right excipients. *J Pharm Sci*. 2022;111(8):2158-2171.
4. Almukainzi M. Assessment of oral solid dosage forms administration manner and acceptability. *Pharmacia*. 2021;68(2):393-400.
5. Barenie RE, Kesselheim AS, Gagne JJ, et al. Preferences for and experiences with pill appearance changes: national surveys of patients and pharmacists. *Am J Manag Care*. 2020;26(8):340-347.
6. Bracken L, McDonough E, Ashleigh S, et al. Can children swallow tablets? Outcome data from a feasibility study to assess the acceptability of different-sized placebo tablets in children (creating acceptable tablets (CAT)). *BMJ Open*. 2020;10(10):e036508.
7. Bracken L, Habashy R, McDonough E, et al. Creating acceptable tablets 3D (CAT 3D): a feasibility study to evaluate the acceptability of 3D printed tablets in children and young people. *Pharmaceutics*. 2022;14(3):516.
8. Fastø MM, Genina N, Kaae S, Kälvemark Sporrøng S. Perceptions, preferences and acceptability of patient designed 3D printed medicine by polypharmacy patients: a pilot study. *Int J Clin Pharm*. 2019;41(5):1290-1298.

9. Goyanes A, Scarpa M, Kamlow M, Gaisford S, Basit AW, Orlu M. Patient acceptability of 3D printed medicines. *Int J Pharm.* 2017;530(1):71-78.
10. Hofmanová JK, Rajabi-Siahboomi A, Haque S, et al. Developing methodology to evaluate the oral sensory features of pharmaceutical tablet coatings. *Int J Pharm.* 2019;562:212-217.
11. Hofmanová JK, Mason J, Batchelor HK. Sensory aspects of acceptability of bitter-flavoured 7.5 mm film-coated tablets in adults, preschool and school children. *Int J Pharm.* 2020;585:119511.
12. Hummler H, Stillhart C, Meilicke L, et al. Impact of tablet size and shape on the swallowability in older adults. *Pharmaceutics.* 2023;15(4):1042.
13. Kabeya K, Satoh H, Hori S, Sawada Y. Experimental study on patient preferences regarding the shape and size of medical tablets and capsules using three-dimensionally printed plastic model formulations. *Patient Prefer Adherence.* 2021:863-870.
14. Kurczewska-Michalak M, Kardas P, Czajkowski M. Patients' preferences and willingness to pay for solid forms of oral medications—results of the discrete choice experiment in Polish outpatients. *Pharmaceutics.* 2020;12(3):236.
15. Liu F, Ghaffur A, Bains J, Hamdy S. Acceptability of oral solid medicines in older adults with and without dysphagia: a nested pilot validation questionnaire based observational study. *Int J Pharm.* 2016;512(2):374-381.
16. MacKenzie-Smith L, Marchi P, Thorne H, Timeus S, Young R, Le Calvé P. Patient preference and physician perceptions of patient preference for oral pharmaceutical formulations: results from a real-life survey. *Inflamm Intest Dis.* 2018;3(1):43-51.

17. Osborn ZF, Acosta TJP, Lee JC, McNicholl I, McKinnon JE. 2511. Characterization of patient pill preferences from a prospective placebo vs. placebo ease of swallowability study. *Open Forum Infect Dis.* 2019;6(Suppl 2):S871-S872.
18. Ranmal S, Tuleu C. Piloting the children's acceptability of oral formulations (CALF) medicines survey to determine perceptions and practices with paediatrics medicines. *Arch Dis Child.* 2013;98(6):e1-e1.
19. Shariff Z, Kirby D, Missaghi S, Rajabi-Siahboomi A, Maidment I. Patient-centric medicine design: key characteristics of oral solid dosage forms that improve adherence and acceptance in older people. *Pharmaceutics.* 2020;12(10):905.
20. Vallet T, Michelon H, Orlu M, et al. Acceptability in the older population: the importance of an appropriate tablet size. *Pharmaceutics.* 2020;12(8):746.
21. Venables R, Batchelor H, Hodson J, Stirling H, Marriott J. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population. *Int J Pharm.* 2015;480(1):55-62.
22. Wargenau M, Reidemeister S, Klingmann I, Klingmann V. A composite endpoint for acceptability evaluation of oral drug formulations in the pediatric population. *Ther Innov Regul Sci.* 2022;56(6):903-909.